The list of illnesses that seem to benefit from treatment with #GLP1agonists seems to get ever longer, and a study has suggested that #schizophrenia could be an addition.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.socialThe list of illnesses that seem to benefit from treatment with #GLP1agonists seems to get ever longer, and a study has suggested that #schizophrenia could be an addition.
@gmj-georgia.bsky.socialSemaglutide causes more lean mass loss (40%) than diet alone (25%), but a new case series shows resistance training + adequate protein may preserve muscle… #Bodycomposition #Clinicaltrial #GLP1agonists #Leanmass #Obesitymanagement #Bodycomposition #Clinicaltrial #GLP1agonists #Leanmass #Obesity…
@gmj-georgia.bsky.socialMajor meta-analysis in @TheBMJ: popular obesity drugs like semaglutide and tirzepatide produce significant weight loss but do NOT… #BMJ #Cardiovascularrisk #Clinicaloutcomes #GLP1agonists #Metaanalysis #BMJ #Cardiovascularrisk #Clinicaloutcomes #GLP1agonists #Metaanalysis https://news.gmj.ge/o…
@gmj-georgia.bsky.social🔬 Breakthrough in weight-loss pharmacotherapy: Orforglipron, a new once-daily oral tablet, has outperformed semaglutide in a major cl… #Clinicaltrial #Globalhealthaccess #GLP1agonists #Orforglipron #Pharmaceuticalinnovation #Clinicaltrial #Globalhealthaccess #GLP1agonists #Orforglipron #Pharmac…
@medicalspanish.bsky.socialDo you know how to prescribe a GLP-1 agonist in Spanish??? Learn how in this quick reel based on the latest episode of the Medical Spanish Podcast. #learnmedicalspanish #medicalspanishpodcast #docmolly #medicalstudent #medsky #agonistasGLP1 #GLP1agonists #diabetes
@4040rec.bsky.social@gmj-georgia.bsky.socialBreaking: Semaglutide (Wegovy) becomes the first GLP-1 receptor agonist approved to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-a… #Drugapproval #Fibrosis #GLP1agonists #Hepatology #Liverdisease #Drugapproval #Fibrosis #GLP1agonists #Hepatology #Liverdisease …
@gmj-georgia.bsky.socialBreaking: Semaglutide (Wegovy) becomes the first GLP-1 receptor agonist approved to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-a… #Drugapproval #Fibrosis #GLP1agonists #Hepatology #Liverdisease #Drugapproval #Fibrosis #GLP1agonists #Hepatology #Liverdisease …